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  Cytoplasmic Cu/Zn superoxide dismutase (SOD1) is an 
antioxidant enzyme that converts superoxide to hydrogen 
peroxide in cells. Its spatial distribution matches that of 
superoxide  production,  allowing  it  to  protect  cells  from 
oxidative  stress.  SOD1  deficiencies  result  in  embryonic 
lethality and a wide range of pathologies in mice, but little 
i s  k n o w n  a b o u t  n o r m a l  S O D 1  p r o t e i n  e x p r e s s i o n  i n  
developing embryos. In this study, the expression pattern 
of  SOD1  was  investigated  in  post-implantation  mouse 
embryos and extraembryonic tissues, including placenta, 
using Western blotting and immunohistochemical analyses. 
SOD1 was detected in embryos and extraembryonic tissues 
from  embryonic  day  (ED)  8.5  to  18.5.  The  signal  in 
embryos was observed at the lowest level on ED 9.5-11.5, 
and the highest level on ED 17.5-18.5, while levels remained 
constant in the surrounding extraembryonic tissues during all 
developmental stages examined. Immunohistochemical analysis 
of SOD1 expression on ED 13.5-18.5 revealed its ubiquitous 
distribution throughout developing organs. In particular, 
high  levels  of  SOD1  expression  were  observed  in  the 
ependymal  epithelium  of  the  choroid  plexus,  ganglia, 
sensory cells of the olfactory and vestibulocochlear epithelia, 
blood  cells  and  vessels,  hepatocytes  and  hematopoietic 
cells of the liver, lymph nodes, osteogenic tissues, and skin. 
Thus, SOD1 is highly expressed at late stages of embryonic 
development  in  a  cell-  and  tissue-specific  manner,  and 
can function as an important antioxidant enzyme during 
organogenesis in mouse embryos.
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Introduction 
  In mammalian tissues, reactive oxygen species (ROS), 
such as superoxide radicals (O
2- ), hydroxyl radicals (OH
- ) 
and hydrogen peroxide (H2O2), are continuously generated 
during aerobic metabolism. ROS modulate multiple 
cellular processes, including proliferation, differentiation, 
and signaling. However, excessive generation of ROS can 
cause detrimental changes, such as lipid peroxidation, 
DNA breakage, protein degradation, and enzyme 
inactivation [6,26].
  The superoxide dismutase (SOD) family is a ubiquitously 
distributed group of enzymes that efficiently catalyze the 
dismutation of O
2- [15]. The cytoplasmic Cu/Zn SOD 
(SOD1) is located in multiple intracellular compartments 
including the cytosol, nucleus, lysosome, and mitochondrial 
intermembrane space [4,20], while the manganese SOD 
(SOD2) is only located in mitochondria [28].
    Mice lacking SOD1 develop a range of pathologies, 
including hepatocellular carcinoma, cochlear hair cell loss, 
vascular dysfunction, anemia, acceleration of age-related 
loss of muscle mass, an earlier incidence of cataracts, and 
a reduced lifespan [7,8,13,16,17,23]. Pregnant female 
mice lacking SOD1 experienced an increased incidence of 
lethality in their embryos [11]. Co-treatment with SOD 
alleviated the teratogenicity of a broad range of embryonic 
cytotoxic agents, including ethanol and hyperglycemia 
[3,29]. SOD1 mRNA was detected in all embryos at 
embryonic day (ED) 7.5-18.5 and was expressed in a cell- 
and tissue-specific manner in developing organs [30]. In 
this study, we investigated the expression patterns of 
SOD1 protein during embryonic development, using 
Western blotting and immunohistochemical analysis, to 
better understand the function of SOD1 in embryogenesis. 234    Jung-Min Yon et al.
Fig. 1. Relative expression levels of SOD1 protein in developing embryos (A) and extraembryonic tissues (B). Total protein was 
extracted from mouse embryos and extraembryonic tissues on embryonic day (ED) 8.5 to 18.5, and Western blotting was performed 
using an anti-SOD1 antibody. β-actin was used as an internal standard.
Materials and Methods
Experimental animals
  Male and female ICR mice (8 to 10 weeks old) were 
purchased from a commercial breeder, Biogenomics 
(Korea). All animals were housed in polycarbonate cages 
and acclimatized for 1 wk. The environmental conditions 
were controlled, with an ambient temperature of 21 ± 2
oC, 
relative humidity of 55% ± 10%, air ventilation rate of 10 
cycles per h, and a 12：12 h light：dark cycle. The animals 
were fed a standard mouse chow (Samyang, Korea) and tap 
water ad libitum throughout the experimental period. All 
experiments were approved and performed according to 
the “Guide for Care and Use of Animals” (Chungbuk 
National University Animal Care Committee, Korea).
Preparation of embryos and extraembryonic tissues
  One male and two female mice were housed in cages for 
mating. Successful mating was confirmed by the presence 
of a copulation plug in the vagina. The day on which the 
vaginal plug was observed was designated ED 0.5. 
Pregnant mice were sacrificed under pentobarbital anesthesia 
on ED 8.5-18.5, and embryos and extraembryonic tissues, 
including the placenta, were dissected.
Protein extraction and Western blotting analysis 
  Total protein was extracted from mouse embryos and 
extraembryonic tissues taken on ED 8.5-18.5. Tissue 
samples were homogenized in lysis buffer (50 mM 
HEPES, 150 mM NaCl, 1 mM EDTA, 10% glycerol, 1% 
Triton X-100, 1 mM phenylmethylsulfonyl fluoride, 1 
μg/ml aprotinin, 0.5 mM sodium orthovanadate, and 20 
mM sodium pyrophosphate). The lysates were clarified by 
centrifugation at 14,000 rpm for 10 min and incubated at 95
oC 
in loading buffer (0.125 M Tris-HCl (pH 6.8), 4% SDS, 
20% glycerol, 10% 2-mercaptoethanol, and 0.002% 
bromophenol blue) for 5 min before electrophoresis. 
Aliquots containing 60 μg of total protein were separated 
by SDS-PAGE (using 10% polyacrylamide gels) and 
transferred to nitrocellulose membranes (Immobilon; 
Millipore, USA). The membranes were blocked with 5% 
non-fat milk in Tris-buffered saline [TBS; 25 mM Tris (pH 
7.4), 200 mM NaCl] for 1 h at room temperature to 
eliminate nonspecific binding, and were then incubated 
with the primary antibodies (diluted 1：1,000 in 5% non-fat 
milk in TBST), polyclonal rabbit anti-SOD1 (Stressgen, 
Canada) and polyclonal rabbit anti-β-actin (Cell Signaling, 
USA). Next, membranes were incubated with a horseradish 
peroxidase-conjugated secondary antibody (1：1,000; Cell 
Signaling, USA) for 1 h at room temperature, visualized 
using a Western Lightning Chemiluminescence reagent 
(Perkin-Elmer Life Sciences, USA) according to the 
manufacturer's protocol, and photographed (Gel Doc EQ; 
Bio-Rad, USA). Immunoreactive bands were quantified 
and normalized using PDQuest Image software (Bio-Rad, 
USA). Experiments were performed in triplicate, and data 
are presented as mean ± SD.
Immunohistochemistry
    For immunohistochemical analysis, mouse embryos 
obtained on ED 13.5-18.5 were fixed in Bouin solution. 
Tissue sections were deparaffinized with xylene and 
rehydrated through an ethanol gradient. Endogenous 
peroxidase activity was quenched by 0.3% hydrogen Localization and level of SOD1 in developing mouse embryos    235
Fig. 2. Immunohistochemistry using a SOD1 antibody on sagittal sections of developing mouse embryos. (A) Embryonic day (ED) 17.5
cerebral cortex (outer layer; asterisk) (×100). (B) ED 17.5 pyramidal cells of cerebral cortex (×400). (C) ED 17.5 cerebellum (×100).
(D) ED 17.5 choroid plexus (×100). (E) ED 15.5 Rathke’s pouch (×400). (F) ED 17.5 Rathke’s pouch (×100). (G) ED 15.5 spinal 
ganglion (×400). (H) ED 16.5 inner ear in bony labyrinth (×40). (I) ED 16.5 sensory epithelium of inner ear (×400). (J) ED 17.5 nasal
cavity (×100), Bowman’s glands (arrow). (K) ED 17.5 olfactory epithelium (×400). (L) ED 18.5 eye (×40), iris (arrow) and pigment 
layer (arrowhead) of retina. (M) ED 16.5 lung (×40). (N) ED 16.5 lung (×200), terminal bronchial epithelia of lung (asterisk). (O) ED 
17.5 heart (×100). (P) ED 13.5 blood cells (×400). (Q) ED 17.5 blood vessel (×200; asterisk). (R) ED 16.5 stomach (×200). (S) ED 16.5
goblet cell (arrow) and Paneth cell (arrowhead) of intestine (×400). (T) ED 17.5 intestine (×100).
peroxide in methanol for 15 min, and then sections were 
washed 4 times in PBS, for 5 min each time. Nonspecific 
binding was blocked with a 20 min incubation in diluted 
normal serum, and sections were incubated for 1 h at 37
oC 
with the SOD1 antibody. Next, sections were incubated for 
30 min at room temperature with a biotinylated secondary 
antibody (Vector, USA) followed by 40 min at room 
temperature with the peroxidase-conjugated biotin-avidin 
complex (Vectastain ABC kit; Vector, USA). Finally, the 
bound peroxidase was revealed by immersing the sections 
in diaminobenzidine (Vector, USA). Sections were 
counterstained with hematoxylin, rehydrated for 15 min in 236    Jung-Min Yon et al.
Fig. 3. Immunohistochemistry using a SOD1 antibody on sagittal sections of developing mouse embryos. (A) Embryonic day (ED) 16.5
liver (×100). (B) ED 16.5 liver (×400). (C) ED 17.5 pancreas (×400). (D) ED 18.5 submandibular gland (×200). (E) ED 16.5 kidney 
(×200). (F) ED 14.5 adrenal gland (×100). (G) ED 16.5 adrenal gland (×200). (H) ED 17.5 thymus (×200). (I) ED 16.5 lymph node (×40).
(J) ED 16.5 bone (×200). (K) ED 18.5 bone (×100). (L) ED 14.5 skin (×200). (M) ED 17.5 skin (×100). (N) ED 18.5 collagen fiber-like
tissue (×100). (O) ED 17.5 skin (×100); negative control.
deionized water to remove any precipitated Tris, and then 
dehydrated in a series of ethanol and xylene. Negative 
control experiments for the antibodies were performed as 
above with the omission of the primary antibody.
Results
Expression  of  SOD1  in  developing  embryos  and 
extraembryonic tissues
  Using Western blot analysis with β-actin as an internal 
standard, SOD1 was detected in all embryos and 
extraembryonic tissues from ED 8.5 to 18.5. The signal in 
embryos was observed at the lowest levels on ED 9.5-11.5 
and the highest levels on ED 17.5-18.5 (Fig. 1A). Extraembryonic 
expression of SOD1 remained constant throughout all 
stages of embryonic development (Fig. 1B).
Localization pattern of SOD1 during organogenesis
    SOD1 immunoreactivity was detected in various 
embryonic tissues from ED 13.5 to 18.5. The distribution 
and quantitative expression of SOD1 in developing 
embryos are described in detail below (Figs. 2 and 3) and 
are summarized in Table 1. In developing brains, SOD1 
immunoreactivity was detected at moderate levels in the 
external layers (Fig. 2A; asterisk) and pyramidal cells of 
the cerebral cortex on ED 13.5 to 18.5 (Fig. 2B) and in the 
cerebellum on ED 17.5 and 18.5 (Fig. 2C). A strong SOD1 
signal was observed in the ependymal epithelium of the 
choroid plexus on ED 13.5 to 18.5 (Fig. 2D) and in 
Rathke’s pouch (hypophysis) after ED 15.5 (Figs. 2E and 
F). The SOD1 signal was also strong in the developing 
spinal ganglia on ED 13.5 to 17.5, but was present at only 
a moderate level on ED 18.5 (Fig. 2G). Moderate SOD1 Localization and level of SOD1 in developing mouse embryos    237
Table 1. Comparison of cytoplasmic Cu/Zn superoxide dismutase expression in developing embryonic organs following embryonic day
Organs / Embryonic day 13.5 14.5 15.5 16.5 17.5 18.5 
Nervous tissues Cerebral cortex + 　+±±+ +
Choroid plexus ++ ++ ++ ++ +++ ++
Cerebellum + + ± ± + +
Rathke's pouch (hypophysis) + + + ++ ++ +++
Ganglia ++ ++ ++ ++ ++ ++
Spinal cord + + + + ++ ++
Sensory organs Olfactory epithelium + + ++ ++ ++ ++
Inner ear epithelium nc + ++ +++ ++ ++
Respiratory organs Lung Parenchyma ± ± ± + + +
Epithelium ± ± ± ++ ++ ++
Circulatory organs Myocardium ± ± ± ± + ++
Blood cells +++ +++ +++ ++ ++ ++
Blood vessels ++ ++ +++ +++ +++ +++
Digestive organs Intestine Epithelium ± ± + ++ + +
Muscular layer ± ± + + + ++
Liver Hepatocyte +++ +++ +++ +++ +++ ++
Hematopoietic cells +++ ++ ++ ++ ++ ++
Pancreas Acinus ± + + + ++ +
Islet ± + + + + ±
Submandibular gland ± ± + nc ++ ++
Urinary organs Kidney Metanephric corpuscle + + + + ++ ±
Metanephric tubule + + + + + +
Urinary bladder Epithelium nc nc + + nc ±
Muscular layer nc nc ± ± nc ++
Adrenal gland Medulla ++ ++ + + nc ±
Cortex + + + ++ nc ++
Lymphatic organs Thymus nc nc ++ +++ ++ +
Lymph nodes nc ± ++ +++ +++ +++
Osteogenic tissues +++ +++ +++ +++ +++ ++
Skin ± ± ++ +++ +++ +++
*Signal intensity: ±, weak; +, moderate; ++, strong; +++, very strong; nc, not checked. 
immunoreactivity was detected in the spinal cord on ED 
13.5 to 16.5, and the signal was strong on ED 17.5 and 18.5 
(Table 1).
  After ED 15.5, SOD1 was strongly expressed in the 
sensory cells of the cochlear and vestibular epithelia of the 
inner ear (Figs. 2H and I) and in the olfactory cells and 
Bowman’s glands in the olfactory epithelium (Figs. 2J and 
K). In developing eyes, strong SOD1 immunoreactivity 
was observed in the lens fiber and the retinal pigment 
epithelium (RPE) on ED 16.5, and in the iris and RPE on 
ED 18.5 (Fig. 2L).
    In the parenchyma of the developing lung, weak 
expression of SOD1 was observed on EDs 13.5 to 15.5, 
becoming moderate on ED 16.5 to 18.5. Strong SOD1 
immunoreactivity was observed in the bronchial and 
terminal bronchiolar epithelia after ED 15.5 (Figs. 2M and 
N). SOD1 was weakly expressed in the myocardium of the 
developing heart up until ED 16.5, and increased slightly 
after ED 17.5 (Fig. 2O). In contrast, strong SOD1 
immunoreactivity was consistently observed in nucleated 
and enucleated blood cells and in blood vessels (Figs. 2P 
and Q).
    SOD1 was strongly expressed in the basal cells and 
muscular layers of the stomach on ED 16.5 (Fig. 2R). In 
developing intestine, SOD1 expression was moderate in 
the intestinal villi and muscle layers after ED 15.5, but was 
strong in the goblet cells and basal cell part of the crypt of 
Lieberkühn after ED 16.5 (Fig. 2S and T). In the developing 
liver, strong SOD1 immunoreactivity was observed in 
hepatocytes and hematopoietic cells during all periods 
examined (Figs. 3A and B). In the developing pancreas, 
moderate SOD1 immunoreactivity was observed in the 
acinus and islet on ED 14.5 to 16.5. After ED 17.5, the 
SOD1 signal was higher in the acinus than the islet of the 238    Jung-Min Yon et al.
pancreas (Fig. 3C). Strong SOD1 immunoreactivity was 
observed in secretory acini and ducts of the submandibular 
glands on EDs 17.5 to 18.5 (Fig. 3D).
  In the developing kidney, SOD1 immunoreactivity was 
higher in the cortex than in the medulla, but the signal 
intensity was moderate in the metanephric corpuscles and 
tubules on ED 13.5 to 16.5 (Fig. 3E). On ED 17.5, a strong 
SOD1 signal was observed in the glomeruli, but moderate 
in the tubules. However, the signal intensity in tubules and 
glomeruli was reversed on ED 18.5 (Table 1). Moderate 
SOD1 immunoreactivity was observed in the luminal 
epithelium of the urinary bladder on EDs 15.5 and 16.5. On 
ED 18.5, SOD1 immunoreactivity was strong in the 
surrounding muscular layers, but was weak in the 
epithelium (Table 1).
  In the developing adrenal glands, SOD1 expression was 
higher in the medulla than in the cortex on EDs 13.5 and 
14.5 but was similar in both areas on ED 15.5. On ED 16.5 
to 18.5, the SOD1 signal in the cortex had exceeded that 
observed in the medulla (Figs. 3F and G).
  Strong SOD1 expression was observed in the thymus on 
ED 15.5 to 17.5 (Fig. 3H), whereas expression was 
moderate on ED 18.5. In the developing lymph nodes, 
SOD1 expression was weak on ED 14.5 and was high after 
ED 15.5 (Fig. 3I). In the developing bone and cartilage, a 
very strong SOD1 signal was observed in chondrocytes on ED 
13.5 to 18.5 (Figs. 3J and K). Strong SOD1 immunoreactivity 
was observed in the surface epithelium, hair follicles, and 
muscle layers of the skin after ED 15.5 (Figs. 3L and M) 
and in a collagen fiber-like tissue on ED 18.5 (Fig. 3N).
Discussion
  ROS are important in normal developmental processes, 
such as progression to the early stage, neuronal 
differentiation, and digit formation. However, excessive 
production of ROS can cause severe embryonic damage, 
resulting in embryonic death, preeclampsia, or congenital 
anomalies in placentation [6,26]. SOD1 plays a major role 
in antioxidant defense by converting O
2- to H2O2 and water 
[15]. Recently, we demonstrated that SOD1 transcripts were 
present at all embryonic stages [30]. Here, we confirm the 
expression pattern of SOD1 protein during normal 
embryonic development. SOD1 was detected throughout 
all embryonic stages, in both embryonic and 
extraembryonic tissues, from ED 8.5 to 18.5. The SOD1 
signal was increased at late stages of embryonic 
development, but maintained a constant level of expression 
in extraembryonic tissues during organogenesis. SOD1 
immunoreactivity was particularly strong in metabolically 
active sites and in protective tissues, such as the skin and 
lung, at late gestation.
  Uteroplacental circulation is established after implantation. 
The placenta receives nutrients, oxygen, antibodies, and 
hormones from the mother's blood and passes out waste 
[10]. The expression of SOD1 within the human placenta 
suggests that it might serve an important function at the 
maternal-fetal interface [27]. The oxygen requirements in 
rodent embryos vary during embryo development [2]. As 
the fetus moves from a hypoxic to a relatively hyperoxic 
environment, accompanying changes in antioxidant enzymes 
constitute a compensatory mechanism aimed at protecting 
the newborn from oxidative stress [14].
  SOD1 accumulates in many neuronal populations, but it 
is particularly abundant in motor neurons of the spinal cord 
[21]. A number of sporadic and familial motor neuron 
diseases result from point mutations in the gene encoding 
SOD1 on human chromosome 21 [24]. In this study, SOD1 
expression was higher in the spinal cord and spinal ganglia 
than in the brain during organogenesis.
    SOD1 immunoreactivity was ubiquitously present in 
developing organs and was particularly strong in the 
ependymal epithelium of the choroid plexus, ganglia, 
sensory cells of the olfactory and vestibulocochlear 
epithelia, blood cells and vessels, hepatocytes and 
hematopoietic cells of livers, lymph nodes, osteogenic 
tissues, and skin during organogenesis. These results are in 
agreement with the expression patterns of SOD1 transcripts 
in most tissues and metabolically active sites [30]. SOD1 
levels increase in mature cells to inhibit oxidative stress 
induced by exogenous materials, such as alcohol, kanamycin, 
6-hydroxydopamine, and 1-methyl-4-phenylpyridinium 
[1,22]. SOD1 immunoreactivity is detected in the 
epithelial cells of the gastrointestinal tract, respiratory 
tract, pancreatic islets, and kidneys during late gestation in 
rats [18,19].
  ROS are vital to normal developmental processes, such as 
proliferation and differentiation [6]. SOD1 is distributed 
primarily in tissues and cells that are frequently exposed to 
O
2- or its metabolites. In this study, strong SOD1 
immunoreactivity was observed in sites of active 
differentiation and proliferation, such as chondrocytes of 
osteogenic tissues, hematopoietic cells of the liver, and 
circulatory blood cells. Erythrocytes use SOD1 to 
scavenge O
2-, but carry only the SOD1 protein, not mRNA, 
as they lack mitochondria. SOD1 deficiency leads to 
increased erythrocyte vulnerability, as a consequence of 
increased oxidation of proteins and lipids. The short 
lifespan of erythrocytes in SOD1−/− mice has been 
attributed to both endogenous and environmental factors 
[12]. Neutrophils produce enormous quantities of O
2- 
through the activity of oxidant-generating systems [25]. 
High levels of SOD1 activity were detected in cartilage and 
connective tissues [9], and a low molecular weight mimetic 
of SOD attenuates chronic inflammation, tissue damage, 
and bone damage associated with collagen-induced arthritis 
[5]. Thus, SOD1 may act as an important antioxidant in 
osteogenesis and hematopoiesis during embryonic development.Localization and level of SOD1 in developing mouse embryos    239
  SOD1 levels vary widely in different cell types, and even 
within a particular cell type, during the course of embryonic 
development. SOD1 may play a crucial role as an 
antioxidant against ROS in cellular differentiation, regulation, 
and signaling during murine embryonic development.
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